Domestically developed biosimilar products are prominent in the large anticancer drug Asastin market. Samsungbioepis' Onbevzi exceeded 10 billion won in quarterly sales in the first two years of its release, showing a 35% share. It is said that Boryung, which was the first biosimilar to enter the market and has differentiated strengths in anticancer drug sales, added to sales and maximized synergy.

According to IQVIA, a pharmaceutical research institute on the 29th, the market size of Bevacizumab in the first half of last year was 59.9 billion won, up 36.1% from the same period last year. Sales in the first quarter were 29.5 billion won, up 39.8% from the previous year, and continued to grow at 30.4 billio